Impact Of Weight-Related Utilities On The Cost-Effectiveness Of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Third-Line Therapy In Type 2 Diabetes Mellitus (T2dm) In A Canadian Setting
May 1, 2015, 00:00
10.1016/j.jval.2015.03.361
https://www.valueinhealthjournal.com/article/S1098-3015(15)00418-0/fulltext
Title :
Impact Of Weight-Related Utilities On The Cost-Effectiveness Of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Third-Line Therapy In Type 2 Diabetes Mellitus (T2dm) In A Canadian Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00418-0&doi=10.1016/j.jval.2015.03.361
First page :
A62
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
1463